食管癌免疫检查点抑制剂临床应用全程管理专家共识
Expert consensus on the whole-process management of clinical application of immune checkpoint inhibitors for esophageal cancer
中国抗癌协会食管肿瘤整合康复专业委员会 陈小兵
摘要
随着肿瘤免疫治疗领域的快速发展,以程序性死亡受体-1(programmed death-1,PD-1)及程序性死亡受体配体-1(programmed death ligand-1,PD-L1)为核心的免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在食管癌的治疗中取得了显著进展,多项临床试验已证实了 ICIs在食管癌治疗中的疗效与安全性,并逐步改写食管癌的治疗模式.目前,ICIs已在我国食管癌的治疗中得到广泛应用,为了更好地指导食管癌ICIs应用的全程管理,提升食管癌ICIs应用的科学性和规范性,中国抗癌协会食管肿瘤整合康复专业委员会组织国内相关领域专家,经过多轮深入讨论和修改,系统性地梳理了国内外最新的指南和循证医学证据,并充分考虑了我国临床实践的具体情况,形成本专家共识.
Abstract
With the rapid development in the field of tumor immunotherapy,immune checkpoint inhibitors(ICIs)centered on programmed death-1(PD-1)and programmed death ligand-1(PD-L1)have made significant progress in the treatment of esophageal cancer.Several studies have confirmed the effectiveness and safety of ICIs in the treatment of esophageal cancer,and have gradually changed the landscape for treating advanced esophageal cancer.At present,ICIs have been widely used in the clinical treatment of esophageal cancer in China.In order to better guide the whole-process management of esophageal cancer ICIs application,improve the scientificity and standardization of esophageal cancer ICIs application,the China Anti-cancer Association Esophageal Tumor Integration Rehabilitation Professional Committee organized domestic experts in related fields to systematically sort out the latest domestic and foreign guidelines and evidence-based medical evidence through multiple rounds of discussions and revisions,and reach a consensus among expert in this review by fully considered the specific situation of clinical practice in China.
关键词
食管癌/免疫检查点抑制剂/全程管理/专家共识Key words
Esophageal cancer/Immune checkpoint inhibitor/Whole-process management/Expert consensus引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据